Aster DM’s Big Bet on Scale

$ASTERDM Aster DM Healthcare is pursuing an aggressive acquisition-led expansion. The merger with CARE Hospitals, KIMSHEALTH and Evercare creates a network of 39 hospitals across southern and central India, with a goal of crossing 15,000 beds and scaling deeper into tier-2 and tier-3 cities. For shareholders, the core issue is whether this rapid inorganic growth is truly value accretive or just about getting bigger. The combined entity reported sales of about ₹9,273 crore, up 14% year-on-year, with EBITDA margin of 21.7% and ROCE of 21.1%, an improvement of nearly 300 bps. Aster’s standalone Q4 FY26 performance was strong too: revenue grew 18% to around ₹1,182 crore, operating EBITDA rose 31% to roughly ₹253 crore, and net profit jumped 45% to about ₹153 crore. These trends indicate that rising scale is supporting better profitability and capital efficiency rather than diluting returns, which is positive for long-term investors. The market has already rewarded this trajectory. Over the past year, Aster’s share price has moved from roughly ₹590 to above ₹800 as investors price in synergies and network benefits. At the same time, the stock now trades at a rich multiple, with valuation metrics implying high expectations and limited room for error if integration or growth slows. That makes the current strategy attractive but not low-risk. Management is shifting focus from merely adding beds to improving case mix and specialty depth, with mature hospitals delivering mid-teens growth and healthy margins. Oncology and other complex specialties are expected to drive incremental returns, while most new capacity is through brownfield expansions, which typically carry lower execution risk. For shareholders, Aster DM’s large-scale integration plan can be beneficial if ROCE stays strong and margins keep improving, but the premium valuation and execution challenges mean the upside comes with meaningful risk.